Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Dacarbazine; Temozolomide

Criteria

Inclusion Criteria:

• Diagnosed with late stage malignant melanoma

• Aged 18 or over

• Female patients must be post-menopausal or with negative urine pregnancy test if pre-menopausal

Exclusion Criteria:

• Any previous radiotherapy or chemotherapy (palliative radiotherapy is acceptable)

• Participation in any other trial with an investigational product within the previous 30 days